News updates


  • image
    27 JUN

    Prolonged duration of COVID-19 vaccine-induced lymphadenopathy

    The Netherlands Pharmacovigilance Centre Lareb has received reports of enlarged lymph nodes after COVID-19 vaccination that do n...

  • image
    30 MAY

    Possible ischaemic colitis after bisacodyl use

    The Netherlands Pharmacovigilance Centre Lareb received two reports of ischaemic colitis after bisacodyl use. Ischaemic colitis often resolves s...

  • image
    28 MAY

    Anaphylactic reaction to the complex of rocuronium and sugammadex

    The sugammadex-rocuronium complex can cause severe allergic reactions. Also in patients who are not allergic to one of the in...

  • image
    15 MAY

    Agnes Kant appointed as professor at Leiden University

    Epidemiologist and director of the Netherlands Pharmacovigilance Centre Lareb, Agnes Kant, has been appointed as professor in pharmacovi...

  • image
    19 APR

    Multi-national European cohort event monitoring studies on COVID-19 vaccines

    Published results from the multi-national European cohort event monitoring show that most participants experience ...

  • image
    23 JAN

    More research needed into Long COVID-like adverse events after COVID-19 vaccination

    The Netherlands Pharmacovigilance Centre Lareb has received reports of a combination of adverse events simi...

  • image
    19 DEC

    Sudden Sensorineural Hearing Loss and COVID-19 vaccines

    Until January 10th 2023, the Netherlands Pharmacovigilance Centre Lareb received 109 reports of  Sudden Sensorineural Hearing Loss (SSN...

  • image
    08 DEC

    Side effects of Tea Tree Oil

    The World Health Organization (WHO) received 159 reports of complaints associated with the use of  tea tree oil products. Skin complaints such as rash, hypersens...

  • image
    15 NOV

    Themes in the course of Adverse Drug Reactions from a patient perspective

    Pharmacovigilance centre Lareb has published a study structuring themes in the course of adverse drug reactions (ADRs...